Peptides derived from the two regulatory domains of p53 are recognized by two p53-activating antibodies

Peptides

Volumn 24, Issue 3, 2003, Pages 339-345

  Portefaix, Jean Michel ^a   Del Rio, Maguy ^a   Granier, Claude ^a   Roquet, Françoise ^a   Pau, Bernard ^a   Navarro Teulon, Isabelle ^a  

^a CNRS   (France)

Author keywords

Epitope mapping; Monoclonal antibodies; p53; Phage display; SPOT

Indexed keywords

ASPARAGINYLHISTIDYLLYSYLASPARTYLTHREONYLPROLYLALANYLTRYPTOPHYLARGINYLASP ARA GINYLARGINYLGLUTAMINYLPROLYLTHREONYLTYROSINE; ASPARAGINYLPROLYLMETHIONYLTRYPTOPHYLARGINYLGLUTAMYLLYSYLGLUTAMINYLALANYL PHE NYLALANYLISOLEUCYLTHREONYLALANYLPROLYLVALINE; ASPARAGINYLSERYLASPARAGINYLALANYLARGINYLPROLYLPROLYLSERYLALANYLVALYLTHRE ONY LTHREONYLARGINYLVALYLVALINE; ASPARAGINYLTHREONYLSERYLARGINYLARGINYLPROLYLHISTIDYLASPARAGINYLALANYLISO LEU CYLPROLYLHISTIDYLALANYLPROLYLTRYPTOPHAN; ASPARAGINYLTHREONYLSERYLLYSYLLEUCYLPROLYLPROLYLGLYCYLHISTIDYLSERYLLYSYLT HRE ONYLSERYLTHREONYLARGININE; GLUTAMINYLSERYLMETHIONYLPROLYLSERYLPHENYLALANYLARGINYLGLYCYLASPARAGINYLA LAN YLPROLYLLYSYLTYROSYLPROLYLGLUTAMINE; GLUTAMYLASPARAGINYLLYSYLMETHIONYLTRYPTOPHYLTYROSYLGLYCYLLYSYLSERYLISOLEU CYL LEUCYLSERYLARGINYLGLUTAMYLARGININE; GLUTAMYLSERYLSERYLARGINYLARGINYLPROLYLTYROSYLSERYLALANYLLEUCYLTHREONYLPR OLY LGLUTAMINYLTYROSYLVALINE; HISTIDYLLEUCYLLYSYLSERYLLYSYLLYSYLGLYCYLGLUTAMINYLSERYLTHREONYLSERYLARGI NYL HISTIDYLLYSYLLYSINE; HISTIDYLTHREONYLSERYLARGINYLMETHIONYLPROLYLTHREONYLARGINYLGLYCYLASPARAGI NYL PROLYLSERYLARGINYLTRYPTOPHYLGLYCINE; LYSYLGLUTAMYLALANYLPROLYLPROLYLTRYPTOPHYLARGINYLSERYLGLUTAMINYLLEUCYLGLU TAM INYLLEUCYLPROLYLASPARTYLTHREONINE; LYSYLLYSYLGLYCYLGLUTAMINYLSERYLTHREONYLSERYLARGINYLHISTIDYLLYSYLLYSYLLEU CYL METHIONYLPHENYLALANYLLYSINE; METHIONYLTHREONYLARGINYLASPARTYLPROLYLARGINYLSERYLPROLYLHISTIDYLSERYLLEU CYL GLYCYLISOLEUCYLALANYLARGININE; SERYLTHREONYLASPARAGINYLLYSYLLYSYLPROLYLVALYLALANYLARGINYLTHREONYLHISTID YLV ALYLLYSYLALANYLPHENYLALANINE; SERYLTHREONYLSERYLLYSYLASPARAGINYLPROLYLLEUCYLASPARAGINYLPROLYLALANYLPRO LYL THREONYLALANYLPROLYLISOLEUCINE; THREONYLPROLYLARGINYLGLYCYLTRYPTOPHYLHISTIDYLHISTIDYLLYSYLGLUTAMINYLALAN YLS ERYLGLUTAMINYLPROLYLPROLYLSERINE; THREONYLPROLYLLYSYLGLYCYLTRYPTOPHYLGLYCYLMETHIONYLGLUTAMYLLEUCYLMETHIONY LAR GINYLISOLEUCYLGLUTAMINYLASPARTYLLEUCINE; THREONYLSERYLASPARAGINYLLYSYLARGINYLPROLYLTHREONYLPHENYLALANYLTHREONYLTH REO NYLASPARAGINYLTYROSYLVALYLGLUTAMINYLGLUTAMINE; THREONYLSERYLASPARAGINYLLYSYLHISTIDYLPROLYLARGINYLSERYLVALYLGLYCYLPROLYL HIS TIDYLTHREONYLLEUCYLSERINE; THREONYLTHREONYLSERYLLYSYLARGINYLPROLYLMETHIONYLPROLYLLYSYLASPARAGINYLSE RYL TYROSYLALANYLPROLYLTHREONINE; TYROSYLTHREONYLSERYLLYSYLASPARAGINYLPROLYLMETHIONYLTHREONYLHISTIDYLLYSYL SER YLASPARTYLTYROSYLARGINYLTYROSINE; TYROSYLTHREONYLSERYLLYSYLHISTIDYLPROLYLARGINYLASPARAGINYLSERYLSERYLPROLY LTH REONYLSERYLSERYLVALINE; EPITOPE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HR231; MONOCLONAL ANTIBODY PAB 421; PROTEIN P53; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANTIGEN BINDING; ANTIGEN RECOGNITION; ARTICLE; CARBOXY TERMINAL SEQUENCE; DNA BINDING; EPITOPE MAPPING; MOLECULAR RECOGNITION; PEPTIDE SYNTHESIS; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN STRUCTURE; REGULATORY MECHANISM; TECHNIQUE;

EID: 0038066459     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-9781(03)00047-0     Document Type: Article

References (21)

1. Abarzua P., LoSardo J.E., Gubler M.L., Neri A. Microinjection of monoclonal antibody PAb421 into human SW480 colorectal carcinoma cells restores the transcription activation function to mutant p53. Cancer Res. 55:1995;3490-3494.
2. Abarzua P., LoSardo J.E., Gubler M.L., Spathis R., Lu Y.A., Felix A.et al. Restoration of the transcription activation function to mutant p53 in human cancer cells. Oncogene. 13:1996;2477-2482.
3. Ahn J., Prives C. The C-terminus of p53: the more you learn the less you know. Nat. Struct. Biol. 8:2001;730-732.
4. Bonnycastle L.L., Mehroke J.S., Rashed M., Gong X., Scott J.K. Probing the basis of antibody reactivity with a panel of constrained peptide libraries displayed by filamentous phage. J. Mol. Biol. 258:1996;747-762.
5. Caron de Fromentel C., Gruel N., Venot C., Debussche L., Conseiller E., Dureuil C.et al. Restoration of transcriptional activity of p53 mutants in human tumour cells by intracellular expression of anti-p53 single chain Fv fragments. Oncogene. 18:1999;551-557.
6. Chiarugi V., Cinelli M., Magnelli L. Acetylation and phosphorylation of the carboxy-terminal domain of p53: regulative significance. Oncol. Res. 10:1998;55-57.
7. Cho Y., Gorina S., Jeffrey P.D., Pavletich N.P. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science. 265:1994;346-355.
8. Harlow E., Crawford L.V., Pim D.C., Williamson N.M. Monoclonal antibodies specific for simian virus 40 tumor antigens. J. Virol. 39:1981;861-869.
9. Hupp T.R., Lane D.P. Allosteric activation of latent p53 tetramers. Curr. Biol. 4:1994;865-875.
10. Hupp T.R., Sparks A., Lane D.P. Small peptides activate the latent sequence-specific DNA binding function of p53. Cell. 83:1995;237-245.
11. Ferrieres G., Villard S., Pugniere M., Mani J.C., Navarro-Teulon I., Rharbaoui F.et al. Affinity for the cognate monoclonal antibody of synthetic peptides derived from selection by phage display. Role of sequences flanking the binding motif. Eur. J. Biochem. 267:2000;1819-1829.
12. Lane D.P. Cancer: p53, guardian of the genome. Nature. 358:1992;15-16.
13. Legros Y., Lacabanne V., d'Agay M.F., Larsen C.J., Pla M., Soussi T. Production of human p53 specific monoclonal antibodies and their use in immunohistochemical studies of tumor cells. Bull. Cancer. 80:1993;102-110.
14. Legros Y., Lafon C., Soussi T. Linear antigenic sites defined by the B-cell response to human p53 are localized predominantly in the amino and carboxy-termini of the protein. Oncogene. 9:1994;2071-2076.
15. Molina F., Laune D., Gougat C., Pau B., Granier C. Improved performances of spot multiple peptide synthesis. Pept. Res. 9:1996;151-155.
16. Muller-Tiemann B.F., Halazonetis T.D., Elting J.J. Identification of an additional negative regulatory region for p53 sequence-specific DNA binding. Proc. Natl. Acad. Sci. USA. 95:1998;6079-6084.
17. Mundt M., Hupp T., Fritsche M., Merkle C., Hansen S., Lane D.et al. Protein interactions at the carboxyl terminus of p53 result in the induction of its in vitro transactivation potential. Oncogene. 15:1997;237-244.
18. Sakaguchi K., Herrera J.E., Saito S., Miki T., Bustin M., Vassilev A.et al. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev. 12:1998;2831-2841.
19. Scott J.K., Smith G.P. Searching for peptide ligands with an epitope library. Science. 27(249):1990;386-390.
20. Selivanova G., Iotsova V., Okan I., Fritsche M., Strom M., Groner B.et al. Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat. Med. 3:1997;632-638.
21. Selivanova G., Ryabchenko L., Jansson E., Iotsova V., Wiman K.G. Reactivation of mutant p53 through interaction of a C-terminal peptide with the core domain. Mol. Cell Biol. 19:1999;3395-3402.